Menu
Back to User profile » Prof. Dr. SeungHwan Lee
Papers published by Prof. Dr. SeungHwan Lee:
Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects
Kim HC, Yang E, Ban MS, Kim YK, Hong SH, Jung J, Jang IJ, Lee S
Drug Design, Development and Therapy 2023, 17:1115-1124
Published Date: 12 April 2023
Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole
Bae S, Kwon J, Lee MH, Yu KS, Lee S
Drug Design, Development and Therapy 2023, 17:497-506
Published Date: 15 February 2023
Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole
Bae S, Kwon J, Lee SB, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:5099-5108
Published Date: 21 December 2021
Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects
Hwang S, Lee DY, Cho JY, Chung JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:2375-2384
Published Date: 1 June 2021
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
Jeon I, Oh J, Kwon YK, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:1735-1747
Published Date: 28 April 2021
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
Yang E, Yoo H, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2021, 15:651-658
Published Date: 17 February 2021
Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
Yoo H, Kim Y, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:5179-5187
Published Date: 24 November 2020
Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects
Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:4493-4502
Published Date: 23 October 2020
Comparison of the Pharmacokinetics of Highly Variable Drugs in Healthy Subjects Using a Partial Replicated Crossover Study: A Fixed-Dose Combination of Fimasartan 120 mg and Atorvastatin 40 mg versus Separate Tablets
Hwang JG, Yu KS, Lee S
Drug Design, Development and Therapy 2020, 14:1953-1961
Published Date: 20 May 2020
A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects
Kim E, Park KR, Jang IJ, Yu KS, Lee S
Drug Design, Development and Therapy 2019, 13:3879-3885
Published Date: 13 November 2019
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
Choi Y, Lee S, Jang IJ, Yu KS
Drug Design, Development and Therapy 2018, 12:2301-2309
Published Date: 24 July 2018
Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet
Lee S, Nam KY, Oh J, Lee S, Cho SM, Choi YW, Cho JY, Lee BJ, Hong JH
Drug Design, Development and Therapy 2018, 12:1413-1420
Published Date: 23 May 2018
Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ
Drug Design, Development and Therapy 2018, 12:1045-1051
Published Date: 30 April 2018
Comparison of tadalafil pharmacokinetics after administration of a new orodispersible film versus a film-coated tablet
Park SI, Heo SH, Kim G, Chang S, Song KH, Kim MG, Jin EH, Kim J, Lee S, Hong JH
Drug Design, Development and Therapy 2018, 12:935-942
Published Date: 20 April 2018
Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians
Lee J, Rhee SJ, Lee S, Yu KS
Drug Design, Development and Therapy 2018, 12:787-794
Published Date: 6 April 2018
Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S
Drug Design, Development and Therapy 2018, 12:331-337
Published Date: 19 February 2018
Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials
Kim S, Lee S, Cho JY, Yoon SH, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:3187-3195
Published Date: 7 November 2017
A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects
Kim YK, Choi MJ, Oh TY, Yu KS, Lee S
Drug Design, Development and Therapy 2017, 11:3171-3177
Published Date: 6 November 2017
Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
Yoon S, Rhee SJ, Heo SJ, Oh TY, Yoon SH, Cho JY, Lee S, Yu KS
Drug Design, Development and Therapy 2017, 11:3127-3135
Published Date: 27 October 2017
A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers
Lee J, Kim BH, Yu KS, Kim HS, Kim JD, Cho JY, Lee S, Gu N
Drug Design, Development and Therapy 2017, 11:1301-1313
Published Date: 24 April 2017
Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects
Shin D, Lee S, Yi S, Yoon SH, Cho JY, Bahng MY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2017, 11:713-723
Published Date: 10 March 2017
Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
Jang K, Kim M, Oh J, Lee S, Cho JY, Yu KS, Choi TK, Lee SH, Lim KS
Drug Design, Development and Therapy 2017, 11:705-711
Published Date: 9 March 2017
Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
Choi Y, Lee S, Cho SM, Kang WH, Nam KY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2016, 10:3021-3028
Published Date: 20 September 2016
Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, Cho JY, Yu KS
Drug Design, Development and Therapy 2016, 10:2525-2534
Published Date: 10 August 2016
Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects
Rhee SJ, Lee S, Yoon SH, Cho JY, Jang IJ, Yu KS
Drug Design, Development and Therapy 2016, 10:1411-1418
Published Date: 13 April 2016
Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers
Yoon S, Lee H, Kim TE, Lee S, Chee DH, Cho JY, Yu KS, Jang IJ
Drug Design, Development and Therapy 2014, 8:123-128
Published Date: 15 January 2014